- United States
- /
- Medical Equipment
- /
- OTCPK:VAPO
Announcing: Vapotherm (NYSE:VAPO) Stock Increased An Energizing 225% In The Last Year
Vapotherm, Inc. (NYSE:VAPO) shareholders have seen the share price descend 29% over the month. Despite this, the stock is a strong performer over the last year, no doubt about that. During that period, the share price soared a full 225%. So some might not be surprised to see the price retrace some. The real question is whether the business is trending in the right direction.
Check out our latest analysis for Vapotherm
Given that Vapotherm didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
In the last year Vapotherm saw its revenue grow by 161%. That's a head and shoulders above most loss-making companies. Meanwhile, the market has paid attention, sending the share price soaring 225% in response. That sort of revenue growth is bound to attract attention, even if the company doesn't turn a profit. The strong share price rise indicates optimism, so there may be a better opportunity for buyers as the hype fades a bit.
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
It's good to see that there was some significant insider buying in the last three months. That's a positive. On the other hand, we think the revenue and earnings trends are much more meaningful measures of the business. So it makes a lot of sense to check out what analysts think Vapotherm will earn in the future (free profit forecasts).
A Different Perspective
Vapotherm boasts a total shareholder return of 225% for the last year. We regret to report that the share price is down 6.2% over ninety days. It may simply be that the share price got ahead of itself, although there may have been fundamental developments that are weighing on it. It's always interesting to track share price performance over the longer term. But to understand Vapotherm better, we need to consider many other factors. Case in point: We've spotted 3 warning signs for Vapotherm you should be aware of.
Vapotherm is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
If you’re looking to trade Vapotherm, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
About OTCPK:VAPO
Vapotherm
A medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally.
Slight and slightly overvalued.